ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

GPCR vs PAHC // EV/EBITDA & P/E VALUATION

Structure Therapeutics Inc. (NASDAQ) VS. Phibro Animal Health Corporation (Class A) (NASDAQ) • 15-METRIC TALLY: GPCR 0 — PAHC 6
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GPCR VS. PAHC) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC GPCR PAHC SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 30.90% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -19.50% 9.90% -29.40 PAHC /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — 19.2x — TIE /valuation <GO>
Free Cash Flow Yield -14.43% 5.08% -19.51 PAHC /fcf-yield <GO>
Operating Margin — 8.50% — TIE /operating-margins <GO>
Net Profit Margin — 3.70% — TIE /net-margins <GO>
Revenue Growth (YoY) — 27.40% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 1.23% -1.23 PAHC /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 2.87 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 1/9 8/9 -7.00 PAHC /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 26.5 56.9 -30.38 PAHC /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 27.5x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $1.56B $1.58B -$13.2M PAHC /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR GPCR REV PAHC REV GPCR GROSS % PAHC GROSS % GPCR FCF PAHC FCF
FY 2025 $0 $1.30B — 30.9% -$225.8M $80.1M
FY 2024 $0 $1.02B — 30.8% -$117.9M $87.6M
FY 2023 $0 $977.9M — — -$79.5M $13.3M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GPCR // BETA —
PAHC // BETA —